CN118946569A - 化疗药物和组织结合小分子的缀合物、其组合物和方法 - Google Patents

化疗药物和组织结合小分子的缀合物、其组合物和方法 Download PDF

Info

Publication number
CN118946569A
CN118946569A CN202380029671.8A CN202380029671A CN118946569A CN 118946569 A CN118946569 A CN 118946569A CN 202380029671 A CN202380029671 A CN 202380029671A CN 118946569 A CN118946569 A CN 118946569A
Authority
CN
China
Prior art keywords
compound
mmol
mixture
stirred
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380029671.8A
Other languages
English (en)
Chinese (zh)
Inventor
余宁辉
楼荣良
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Conway Guangzhou Biotechnology Co ltd
Original Assignee
Conway Guangzhou Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Conway Guangzhou Biotechnology Co ltd filed Critical Conway Guangzhou Biotechnology Co ltd
Publication of CN118946569A publication Critical patent/CN118946569A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/40—Two or more oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
    • C07F15/0086—Platinum compounds
    • C07F15/0093—Platinum compounds without a metal-carbon linkage
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
CN202380029671.8A 2022-02-08 2023-02-03 化疗药物和组织结合小分子的缀合物、其组合物和方法 Pending CN118946569A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2022/075427 2022-02-08
PCT/CN2022/075427 WO2023150899A1 (en) 2022-02-08 2022-02-08 Conjugates of chemotherapy agents and tissue-binding small molecules, compositions and methods thereof
PCT/CN2023/074329 WO2023151513A1 (en) 2022-02-08 2023-02-03 Conjugates of chemotherapy agents and tissue-binding small molecules, compositions and methods thereof

Publications (1)

Publication Number Publication Date
CN118946569A true CN118946569A (zh) 2024-11-12

Family

ID=87563330

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380029671.8A Pending CN118946569A (zh) 2022-02-08 2023-02-03 化疗药物和组织结合小分子的缀合物、其组合物和方法

Country Status (8)

Country Link
US (1) US20250082657A1 (enExample)
EP (1) EP4476226A1 (enExample)
JP (1) JP2025507308A (enExample)
CN (1) CN118946569A (enExample)
AU (1) AU2023217770A1 (enExample)
CA (1) CA3243247A1 (enExample)
IL (1) IL314835A (enExample)
WO (2) WO2023150899A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118515573B (zh) * 2024-07-19 2024-09-27 浙江省产品质量安全科学研究院 一种稳定同位素标记的氘代奥拉氟化合物的合成方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6350756B1 (en) * 2001-01-18 2002-02-26 California Pacific Medical Center Camptothecin derivatives
CN1982313B (zh) * 2005-12-13 2010-12-01 深圳市天和医药科技开发有限公司 10位取代基上含多个有机羧酸基团的喜树碱化合物及其制法与组合物
US20160095939A1 (en) * 2014-10-07 2016-04-07 Immunomedics, Inc. Neoadjuvant use of antibody-drug conjugates
US9150585B2 (en) * 2012-11-13 2015-10-06 Fl Therapeutics Llc Analogs of camptothecin
CN103848840A (zh) * 2012-12-03 2014-06-11 中国人民解放军军事医学科学院毒物药物研究所 喜树碱衍生物及其医药用途
CN105315294B (zh) * 2014-06-26 2018-05-01 王杭祥 7-乙基-10-羟基喜树碱药物前体及其制备方法和应用
CN104447777B (zh) * 2014-11-26 2016-09-14 浙江大学 一种辣椒碱-喜树碱类抗癌药物偶联物及其制备方法和应用
CN106377528B (zh) * 2016-08-19 2019-05-31 湖北医药学院 一种羟基喜树碱戊二酸单酯的药物组合物
CN106588946B (zh) * 2017-01-25 2019-01-22 郑州大学 10-羟基喜树碱衍生物、合成方法及其应用
KR101990214B1 (ko) * 2017-12-12 2019-06-17 고려대학교 산학협력단 표적 특이적 항암 약물전구체
CN109675050A (zh) * 2018-12-27 2019-04-26 浙江工业大学 以喜树碱为母核的类似物与非甾体抗炎药物的偶联物及其制备与应用
CN110372766A (zh) * 2019-06-21 2019-10-25 广州中医药大学(广州中医药研究院) 喜树碱糖类衍生物及其制备方法与应用

Also Published As

Publication number Publication date
WO2023151513A1 (en) 2023-08-17
US20250082657A1 (en) 2025-03-13
AU2023217770A1 (en) 2024-08-22
JP2025507308A (ja) 2025-03-18
WO2023150899A1 (en) 2023-08-17
IL314835A (en) 2024-10-01
CA3243247A1 (en) 2023-08-17
EP4476226A1 (en) 2024-12-18

Similar Documents

Publication Publication Date Title
JP7462985B2 (ja) 芳香族化合物および抗腫瘍薬物の調製におけるその使用
TWI813666B (zh) 一種多功能化合物、其製備方法及其在醫藥上的應用
CN104945401B (zh) Ip化合物及它们在治疗中的应用
KR102659213B1 (ko) Jak1 선택적 억제제
JP5782586B2 (ja) フルオレン、アントラセン、キサンテン、ジベンゾスベロン、及びアクリジンの誘導体、並びに、それらの使用
CN113214278B (zh) 新型Jak1选择性抑制剂及其用途
CN114409653A (zh) 一种桥环并嘧啶并环类化合物及其用途
IL300308A (en) Low molecular weight protein complexes and their applications
JP6884800B2 (ja) メマンチン化合物及びその調整並びにその使用
CN113698390B (zh) 用作ret激酶抑制剂的化合物及其应用
KR20250112279A (ko) 헤테로고리 화합물, 이의 제조 방법 및 용도
JP2023532151A (ja) アリールリン酸化物化合物およびその使用
CN118946569A (zh) 化疗药物和组织结合小分子的缀合物、其组合物和方法
EP1902054B1 (fr) Derives de pyrido[2,3-d]pyrimidine, leur preparation, leur application en therapeutique
KR20240131416A (ko) 거대고리 화합물 및 키나제 억제제로서의 용도
CN116806150A (zh) 新的自分泌运动因子抑制剂
HK40118706A (zh) 化疗药物和组织结合小分子的缀合物、其组合物和方法
CN115304502B (zh) Foxm1抑制剂及其制备方法和应用
CN118076592A (zh) Shp2抑制剂、包含其的药物组合物及其用途
US20240208942A1 (en) Metap-2 inhibitors, pharmaceutical compositions and therapeutic methods thereof
CN118354999A (zh) 一种哒嗪-1(6h)-6-氧代类化合物及其制备方法与应用
EA051840B1 (ru) Бензопиримидиновые соединения и их применение
HK40047523A (en) Novel jak1 selective inhibitors and uses thereof
HK1257006B (en) Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40118706

Country of ref document: HK